Anticonvulsants for alcohol withdrawal

Alcoholic patients suffer from harmful allostatic neuroplastic changes in the brain causing an acute withdrawal syndrome upon cessation of drinking followed by a protracted abstinence syndrome and an increased risk of relapse to heavy drinking. Benzodiazepines have long been the treatment of choice for detoxifying patients and managing alcohol withdrawal syndrome (AWS). Non-benzodiazepine anticonvulsants (NBACs) are increasingly being used both for alcohol withdrawal management and for ongoing outpatient treatment of alcohol dependence, with the goal of either abstinence or harm reduction. This expert narrative review summarizes the scientific basis and clinical evidence supporting the use of NBACs in treating AWS and for reducing harmful drinking patterns. There is less evidence in support of NBAC therapy for AWS, with few placebo-controlled trials. Carbamazepine and gabapentin appear to be the most promising adjunctive treatments for AWS, and they may be useful as monotherapy in select cases, especially in outpatient settings and for the treatment of mild-to-moderate low-risk patients with the AWS. The body of evidence supporting the use of the NBACs for reducing harmful drinking in the outpatient setting is stronger. Topiramate appears to have a robust effect on reducing harmful drinking in alcoholics. Gabapentin is a potentially efficacious treatment for reducing the risk of relapse to harmful drinking patterns in outpatient management of alcoholism. Gabapentin’s ease of use, rapid titration, good tolerability, and efficacy in both the withdrawal and chronic phases of treatment make it particularly appealing. In summary, several NBACs appear to be beneficial in treating AWS and alcohol use disorders.

This is a preview of subscription content, access via your institution.

Access optionsBuy single article

Instant access to the full article PDF.

39,95 €

Price includes VAT (India)

dataLayer.push({"ecommerce":{"currency":"EUR","impressions":[{"name":"Anticonvulsants for the Treatment of Alcohol Withdrawal Syndrome and Alcohol Use Disorders","id":"1179-1934","price":39.95,"brand":"Springer International Publishing","category":"Medicine & Public Health","variant":"ppv-article","quantity":1}]}});

Rent this article via DeepDyve.

function deepDyveResponse(data) { if (data.status === 'ok') { [].slice.call(document.querySelectorAll('.c-box.buybox__rent-article')).forEach(function (article) { article.style.display = 'flex' var link = article.querySelector('.deepdyve-link') if (link) { link.setAttribute('href', data.url) } }) } } var script = document.createElement('script') script.src = '//www.deepdyve.com/rental-link?docId=10.1007/s40263-015-0240-4&journal=1179-1934&fieldName=journal_doi&affiliateId=springer&format=jsonp&callback=deepDyveResponse' document.body.appendChild(script)

Learn more about Institutional subscriptions

.sprcom-buybox-articleSidebar{box-shadow: 0px 0px 5px rgba(51,51,51,0.101);display: flex;flex-wrap: wrap;font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen-Sans, Ubuntu, Cantarell, 'Helvetica Neue', sans-serif;text-align: center; } .sprcom-buybox-articleSidebar *{box-sizing: border-box;line-height: calc(100% + 4px);margin: 0px; } .sprcom-buybox-articleSidebar > *{display: flex;flex-basis: 240px;flex-direction: column;flex-grow: 1;flex-shrink: 1;margin: 0.5px; } .sprcom-buybox-articleSidebar > *{box-shadow: 0 0 0 1px rgba(204,204,204,0.494); } .sprcom-buybox-articleSidebar .c-box__body{display: flex;flex-direction: column-reverse;flex-grow: 1;justify-content: space-between;padding: 6%; } .sprcom-buybox-articleSidebar .c-box__body .buybox__buy{display: flex;flex-direction: column-reverse; } .sprcom-buybox-articleSidebar p{color: #333;font-size: 15px; } .sprcom-buybox-articleSidebar .buybox__price{font-size: 24px;font-weight: 500;line-height: calc(100% + 8px);margin: 20px 0;order: 1; } .sprcom-buybox-articleSidebar form{order: 1; } .sprcom-buybox-articleSidebar .buybox__price-info{margin-bottom: 20px; } .sprcom-buybox-articleSidebar .c-box__heading{background-color: #f0f0f0;color: #333;font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen-Sans, Ubuntu, Cantarell, 'Helvetica Neue', sans-serif;font-size: 16px;margin: 0px;padding: 10px 12px;text-align: center; } .sprcom-buybox-articleSidebar .c-box__button{background-color: #3365A4;border: 1px solid transparent;border-radius: 2px;color: #fff;cursor: pointer;display: inline-block;font-family: inherit;font-size: 16px;max-width: 222px;padding: 10px 12px;text-decoration: none;width: 100%; } .sprcom-buybox-articleSidebar h3{clip: rect(1px, 1px, 1px, 1px);height: 1px;overflow: hidden;position: absolute;width: 1px; } .sprcom-buybox-articleSidebar h2{flex-basis: 100%;margin-bottom: 16px;text-align: left; } .sprcom-buybox-articleSidebar .buybox__institutional-sub, .buybox__rent-article .c-box__body{flex-direction: row; } .sprcom-buybox-articleSidebar .buybox__institutional-sub, .buybox__rent-article .buybox__info{text-align: left; } .sprcom-buybox-articleSidebar .buybox__institutional-sub{background-color: #f0f0f0; } .sprcom-buybox-articleSidebar .visually-hidden{clip: rect(1px, 1px, 1px, 1px);height: 1px;overflow: hidden;position: absolute;width: 1px; } .sprcom-buybox-articleSidebar style{display: none; } ;(function () { var timestamp = Date.now() document.write('') var head = document.getElementsByTagName("head")[0] var script = document.createElement("script") script.type = "text/javascript" script.src = "https://buy.springer.com/assets/js/buybox-bundle-abe5f44a67.js" script.id = "ecommerce-scripts-" + timestamp head.appendChild(script) var buybox = document.querySelector("[data-id=id_"+ timestamp +"]").parentNode ;[].slice.call(buybox.querySelectorAll(".buying-option")).forEach(init) function init(buyingOption, index) { var form = buyingOption.querySelector("form") if (form) { var formAction = form.getAttribute("action") document.querySelector("#ecommerce-scripts-" + timestamp).addEventListener("load", bindModal(form, formAction, timestamp, index), false) } } function bindModal(form, formAction, timestamp, index) { var weHasBrowserSupport = window.fetch && Array.from return function() { console.log("ecommerce-scripts loaded, attempting to init modal …") var Buybox = EcommScripts ? EcommScripts.Buybox : null var Modal = EcommScripts ? EcommScripts.Modal : null if (weHasBrowserSupport && Buybox && Modal) { var modalID = "ecomm-modal_" + timestamp + "_" + index var modal = new Modal(modalID) modal.domEl.addEventListener("close", close) function close() { form.querySelector("button[type=submit]").focus() } var cartURL = "/cart" var cartModalURL = "/cart?messageOnly=1" form.setAttribute( "action", formAction.replace(cartURL, cartModalURL) ) var formSubmit = Buybox.interceptFormSubmit( Buybox.fetchFormAction(window.fetch), Buybox.triggerModalAfterAddToCartSuccess(modal), function() { form.removeEventListener("submit", formSubmit, false) form.setAttribute( "action", formAction.replace(cartModalURL, cartURL) ) form.submit() } ) form.addEventListener("submit", formSubmit, false) document.body.appendChild(modal.domEl) } else { console.log("binding failed:", weHasBrowserSupport, EcommScripts) } } } })() Notes

The term ‘reversibility’ refers to whether the drug binds but is capable of dissociating from the enzyme, or whether it permanently binds the enzyme, thus essentially destroying it. The term ‘selectivity’ refers to whether or not the drug affects either or both MAO-A and MAO-B enzymes.

References

Harwood H. Updating estimates of the economic costs of alcohol abuse in the United States: estimates, update methods, and data. In: National Institute on Alcohol Abuse and Alcoholism (NIAAA), editor. Report prepared by The Lewin Group for the National Institute on Alcohol Abuse and Alcoholism. Rockville: NIAAA; 2000.

Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2007;64(7):830–42.

PubMed Google Scholar

World Health Organization, Management of Substance Abuse Team. Global status report on alcohol and health, 2014. http://apps.who.int/iris/bitstream/10665/112736/1/9789240692763_eng.pdf?ua=1. Accessed 20 Aug 2014.

World Health Organization, Management of Substance Abuse Team. Global status report on alcohol and health. Geneva: World Health Organization; 2011.

Google Scholar

Koob GF. Alcoholism: allostasis and beyond. Alcohol Clin Exp Res. 2003;27(2):232–43.

CAS PubMed Google Scholar

Schuckit MA. Alcohol-use disorders. Lancet. 2009;373(9662):492–501.

PubMed Google Scholar

De Witte P, Pinto E, Ansseau M, Verbanck P. Alcohol and withdrawal: from animal research to clinical issues. Neurosci Biobehav Rev. 2003;27(3):189–97.

PubMed Google Scholar

Addolorato G, Leggio L, Hopf FW, Diana M, Bonci A. Novel therapeutic strategies for alcohol and drug addiction: focus on GABA, ion channels and transcranial magnetic stimulation. Neuropsychopharmacology. 2012;37(1):163–77.

PubMed Central CAS PubMed Google Scholar

Holmes A, Spanagel R, Krystal JH. Glutamatergic targets for new alcohol medications. Psychopharmacology (Berl). 2013;229(3):539–54.

CAS PubMed Google Scholar

Niciu MJ, Mason GF. Neuroimaging in alcohol and drug dependence. Curr Behav Neurosci Rep. 2014;1(1):45–54.

PubMed Central PubMed Google Scholar

Krystal JH, Staley J, Mason G, Petrakis IL, Kaufman J, Harris RA, et al. Gamma-aminobutyric acid type A receptors and alcoholism: intoxication, dependence, vulnerability, and treatment. Arch Gen Psychiatry. 2006;63(9):957–68.

CAS PubMed Google Scholar

Hermann D, Weber-Fahr W, Sartorius A, Hoerst M, Frischknecht U, Tunc-Skarka N, et al. Translational magnetic resonance spectroscopy reveals excessive central glutamate levels during alcohol withdrawal in humans and rats. Biol Psychiatry. 2012;71(11):1015–21.

CAS PubMed Google Scholar

Book SW, Myrick H. Novel anticonvulsants in the treatment of alcoholism. Expert Opin Investig Drugs. 2005;14(4):371–6.

CAS PubMed Google Scholar

White HS, Smith MD, Wilcox KS. Mechanisms of action of antiepileptic drugs. Int Rev Neurobiol. 2007;81:85–110.

CAS PubMed Google Scholar

Mayo-Smith MF. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA. 1997;278(2):144–51.

CAS PubMed Google Scholar

Miller WR, Wilbourne PL. Mesa Grande: a methodological analysis of clinical trials of treatments for alcohol use disorders. Addiction. 2002;97(3):265–77.

PubMed Google Scholar

Benzer DG. Management of alcohol intoxication and withdrawal. American Society of Addiction Medicine. Principles of Addiction Medicine. Chevy Chase: American Society of Addiction Medicine; 1994.

Google Scholar

Becker HC. Kindling in alcohol withdrawal. Alcohol Health ResWorld. 1998;22(1):25–33.

CAS Google Scholar

Minozzi S, Amato L, Vecchi S, Davoli M. Anticonvulsants for alcohol withdrawal. Cochrane Database Syst Rev. 2010;(3):CD005064.

Chance JF. Emergency department treatment of alcohol withdrawal seizures with phenytoin. Ann Emerg Med. 1991;20(5):520–2.

CAS PubMed Google Scholar

Rathlev NK, D’Onofrio G, Fish SS, Harrison PM, Bernstein E, Hossack RW, et al. The lack of efficacy of phenytoin in the prevention of recurrent alcohol-related seizures. Ann Emerg Med. 1994;23(3):513–8.

CAS PubMed Google Scholar

Ambrosio AF, Soares-Da-Silva P, Carvalho CM, Carvalho AP. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res. 2002;27(1–2):121–30.

CAS PubMed Google Scholar

Granger P, Biton B, Faure C, Vige X, Depoortere H, Graham D, et al. Modulation of the gamma-aminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoin. Mol Pharmacol. 1995;47(6):1189–96.

CAS PubMed Google Scholar

Barrons R, Roberts N. The role of carbamazepine and oxcarbazepine in alcohol withdrawal syndrome. J Clin Pharmacy Ther. 2010;35(2):153–67.

CAS Google Scholar

Stuppaeck CH, Pycha R, Miller C, Whitworth AB, Oberbauer H, Fleischhacker WW. Carbamazepine versus oxazepam in the treatment of alcohol withdrawal: a double-blind study. Alcohol Alcohol. 1992;27(2):153–8.

CAS PubMed Google Scholar

Ritola E, Malinen L. A double-blind comparison of carbamazepine and clomethiazole in the treatment of alcohol withdrawal syndrome. Acta Psychiatr Scand. 1981;64(3):254–9.

CAS PubMed Google Scholar

Malcolm R, Myrick H, Roberts J, Wang W, Anton RF, Ballenger JC. The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial. J Gen Intern Med. 2002;17(5):349–55.

PubMed Central CAS PubMed Google Scholar

Malcolm R, Ballenger JC, Sturgis ET, Anton R. Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal. Am J Psychiatry. 1989;146(5):617–21.

CAS PubMed Google Scholar

Lucht M, Kuehn KU, Armbruster J, Abraham G, Gaensicke M, Barnow S, et al. Alcohol withdrawal treatment in intoxicated vs non-intoxicated patients: a controlled open-label study with tiapride/carbamazepine, clomethiazole and diazepam. Alcohol Alcohol. 2003;38(2):168–75.

Kalyoncu OA, Beyazyurek M, Kuru L, Solukcu R, Yazman U. Double-blind comparative trial with carbamazepine vs diazepam treatment of alcohol withdrawal. Eur Neuropsychopharmacol. 1996;6(4):1–2.

Google Scholar

Hillbom M, Tokola R, Kuusela V, Karkkainen P, Kalli-Lemma L, Pilke A, et al. Prevention of alcohol withdrawal seizures with carbamazepine and valproic acid. Alcohol. 1989;6(3):223–6.

Bjorkqvist SE, Isohanni M, Makela R, Malinen L. Ambulant treatment of alcohol withdrawal symptoms with carbamazepine: a formal multicentre double-blind comparison with placebo. Acta Psychiatr Scand. 1976;53(5):333–42.

CAS PubMed Google Scholar

Koethe D, Juelicher A, Nolden BM, Braunwarth WD, Klosterkotter J, Niklewski G, et al. Oxcarbazepine–efficacy and tolerability during treatment of alcohol withdrawal: a double-blind, randomized, placebo-controlled multicenter pilot study. Alcohol Clin Exp Res. 2007;31(7):1188–94.

CAS PubMed Google Scholar

Schik G, Wedegaertner FR, Liersch J, Hoy L, Emrich HM, Schneider U. Oxcarbazepine versus carbamazepine in the treatment of alcohol withdrawal. Addict Biol. 2005;10(3):283–8.

CAS PubMed Google Scholar

Rosenberg G. The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cell Mol LifeSci. 2007;64(16):2090–103.

CAS Google Scholar

Lum E, Gorman SK, Slavik RS. Valproic acid management of acute alcohol withdrawal. Ann Pharmacother. 2006;40(3):441–8.

CAS PubMed Google Scholar

Reoux JP, Saxon AJ, Malte CA, Baer JS, Sloan KL. Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial. Alcohol Clin Exp Res. 2001;25(9):1324–9.

CAS PubMed Google Scholar

Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol. 2006;6(1):108–13.

CAS PubMed Google Scholar

Bonnet U, Banger M, Leweke FM, Maschke M, Kowalski T, Gastpar M. Treatment of alcohol withdrawal syndrome with gabapentin. Pharmacopsychiatry. 1999;32(3):107–9.

CAS PubMed Google Scholar

Mariani JJ, Rosenthal RN, Tross S, Singh P, Anand OP. A randomized, open-label, controlled trial of gabapentin and phenobarbital in the treatment of alcohol withdrawal. Am J Addict. 2006;15(1):76–84.

Myrick H, Malcolm R, Randall PK, Boyle E, Anton RF, Becker HC, et al. A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. Alcohol Clin Exp Res. 2009;33(9):1582–8.

PubMed Central CAS PubMed Google Scholar

Stock CJ, Carpenter L, Ying J, Greene T. Gabapentin versus chlordiazepoxide for outpatient alcohol detoxification treatment. Ann Pharmacother. 2013;47(7–8):961–9.

Bonnet U, Hamzavi-Abedi R, Specka M, Wiltfang J, Lieb B, Scherbaum N. An open trial of gabapentin in acute alcohol withdrawal using an oral loading protocol. Alcohol Alcohol. 2010;45(2):143–5.

Di Nicola M, Martinotti G, Tedeschi D, Frustaci A, Mazza M, Sarchiapone M, et al. Pregabalin in outpatient detoxification of subjects with mild-to-moderate alcohol withdrawal syndrome. Hum Psychopharmacol. 2010;25(3):268–75.

PubMed Google Scholar

Martinotti G, di Nicola M, Frustaci A, Romanelli R, Tedeschi D, Guglielmo R, et al. Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi-centre, randomized, single-blind comparison trial. Addiction. 2010;105(2):288–99.

PubMed Google Scholar

Forg A, Hein J, Volkmar K, Winter M, Richter C, Heinz A, et al. Efficacy and safety of pregabalin in the treatment of alcohol withdrawal syndrome: a randomized placebo-controlled trial. Alcohol Alcohol. 2012;47(2):149–55.

Richter C, Hinzpeter A, Schmidt F, Kienast T, Preuss UW, Plenge T, et al. Levetiracetam for the treatment of alcohol withdrawal syndrome: a multicenter, prospective, randomized, placebo-controlled trial. J Clin Psychopharmacol. 2010;30(6):720–5.

CAS PubMed Google Scholar

Vogl C, Mochida S, Wolff C, Whalley BJ, Stephens GJ. The synaptic vesicle glycoprotein 2A ligand levetiracetam inhibits presynaptic Ca2+ channels through an intracellular pathway. Mol Pharmacol. 2012;82(2):199–208.

CAS PubMed Google Scholar

White HS. Mechanism of action of newer anticonvulsants. J Clin Psychiatry. 2003;64(Suppl 8):5–8.

CAS PubMed Google Scholar

Perucca E. Clinical pharmacology and therapeutic use of the new antiepileptic drugs. Fundam Clin Pharmacol. 2001;15(6):405–17.

CAS PubMed Google Scholar

McElroy SL, Kotwal R, Hudson JI, Nelson EB, Keck PE. Zonisamide in the treatment of binge-eating disorder: an open-label, prospective trial. J Clin Psychiatry. 2004;65(1):50–6.

CAS PubMed Google Scholar

Ueda Y, Doi T, Tokumaru J, Willmore LJ. Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Brain Res Mol Brain Res. 2003;116(1–2):1–6.

Okada M, Kaneko S, Hirano T, Mizuno K, Kondo T, Otani K, et al. Effects of zonisamide on dopaminergic system. Epilepsy Res. 1995;22(3):193–205.

CAS PubMed Google Scholar

Okada M, Hirano T, Kawata Y, Murakami T, Wada K, Mizuno K, et al. Biphasic effects of zonisamide on serotonergic system in rat hippocampus. Epilepsy Res. 1999;34(2–3):187–97.

CAS PubMed Google Scholar

Asanuma M, Miyazaki I, Diaz-Corrales FJ, Kimoto N, Kikkawa Y, Takeshima M, et al. Neuroprotective effects of zonisamide target astrocyte. Ann Neurol. 2010;67(2):239–49.

CAS PubMed Google Scholar

Sonsalla PK, Wong LY, Winnik B, Buckley B. The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010;221(2):329–34.

PubMed Central CAS PubMed Google Scholar

Krupitsky EM, Rudenko AA, Burakov AM, Slavina TY, Grinenko AA, Pittman B, et al. Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Alcohol Clin Exp Res. 2007;31(4):604–11.

CAS PubMed Google Scholar

Choi E, Ki SW, Kim SE, Kim JW, Park JK. The efficacy and safety of topiramate in the treatment of alcohol withdrawal. J Korean Neuropsychiatr Assoc. 2005;44(3):328–33.

Google Scholar

Rustembegovic A, Sofic E, Kroyer G. A pilot study of Topiramate (Topamax) in the treatment of tonic-clonic seizures of alcohol withdrawal syndromes. Med Arhiv. 2002;56(4):211–2.

PubMed Google Scholar

Rubio G, Lopez-Munoz F, Ponce G, Pascual JM, Martinez-Gras I, Ferre F, et al. Zonisamide versus diazepam in the treatment of alcohol withdrawal syndrome. Pharmacopsychiatry. 2010;43(7):257–62.

CAS PubMed Google Scholar

Tzschentke TM, Schmidt WJ. Glutamatergic mechanisms in addiction. Mol Psychiatry. 2003;8(4):373–82.

CAS PubMed Google Scholar

Minuk GY, Rockman GE, German GB, Duerksen DR, Borrett G, Hoeschen L. The use of sodium valproate in the treatment of alcoholism. J Addict Dis. 1995;14(2):67–74.

CAS PubMed Google Scholar

Brady KT, Myrick H, Henderson S, Coffey SF. The use of divalproex in alcohol relapse prevention: a pilot study. Drug Alcohol Depend. 2002;67(3):323–30.

CAS PubMed Google Scholar

Brady KT, Myrick H, Henderson S, Coffey SF. The use of divalproex in alcohol relapse prevention: a pilot study. Drug Alcohol Depend. 2002;67(3):323–30.

CAS PubMed Google Scholar

Salloum IM, Cornelius JR, Daley DC, Kirisci L, Himmelhoch JM, Thase ME. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry. 2005;62(1):37–45.

CAS PubMed Google Scholar

Kemp DE, Gao K, Ganocy SJ, Elhaj O, Bilali SR, Conroy C, et al. A 6-month, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid-cycling bipolar disorder and Co-occurring substance abuse or dependence. J Clin Psychiatry. 2009;70(1):113–21.

PubMed Central CAS PubMed Google Scholar

Mueller TI, Stout RL, Rudden S, Brown RA, Gordon A, Solomon DA, et al. A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcohol Clin Exp Res. 1997;21(1):86–92.

CAS PubMed Google Scholar

Croissant B, Diehl A, Klein O, Zambrano S, Nakovics H, Heinz A, et al. A pilot study of oxcarbazepine versus acamprosate in alcohol-dependent patients. Alcohol Clin Exp Res. 2006;30(4):630–5.

CAS PubMed Google Scholar

Martinotti G, Di Nicola M, Romanelli R, Andreoli S, Pozzi G, Moroni N, et al. High and low dosage oxcarbazepine versus naltrexone for the prevention of relapse in alcohol-dependent patients. Hum Psychopharmacol. 2007;22(3):149–56.

CAS PubMed Google Scholar

Kalyoncu A, Mirsal H, Pektas O, Unsalan N, Tan D, Beyazyurek M. Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: a potent anti-craving effect? J Psychopharmacol. 2005;19(3):301–5.

CAS PubMed Google Scholar

Pollack MH, Roy-Byrne PP, Van Ameringen M, Snyder H, Brown C, Ondrasik J, et al. The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J Clin Psychiatry. 2005;66(11):1401–8.

CAS PubMed Google Scholar

Paparrigopoulos T, Tzavellas E, Karaiskos D, Malitas P, Liappas I. An open pilot study of tiagabine in alcohol dependence: tolerability and clinical effects. J Psychopharmacol. 2010;24(9):1375–80.

CAS PubMed Google Scholar

Fehr C, Hohmann N, Grunder G, Dielentheis TF, Buchholz HG, Chechko N, et al. Tiagabine does not attenuate alcohol-induced activation of the human reward system. Psychopharmacology (Berl). 2007;191(4):975–83.

CAS PubMed Google Scholar

Sarid-Segal O, Piechniczek-Buczek J, Knapp C, Afshar M, Devine E, Sickles L, et al. The effects of levetiracetam on alcohol consumption in alcohol-dependent subjects: an open label study. Am J Drug Alcohol Abuse. 2008;34(4):441–7.

PubMed Google Scholar

Zalewska-Kaszubska J, Bajer B, Czarnecka E, Dyr W, Gorska D. Voluntary alcohol consumption and plasma beta-endorphin levels in alcohol preferring rats chronically treated with levetiracetam: a preliminary study. Physiol Behav. 2011;102(5):538–41.

CAS PubMed Google Scholar

Mariani JJ, Levin FR. Levetiracetam for the treatment of co-occurring alcohol dependence and anxiety: case series and review. Am J Drug Alcohol Abuse. 2008;34(6):683–91.

PubMed Central PubMed Google Scholar

Fertig JB, Ryan ML, Falk DE, Litten RZ, Mattson ME, Ransom J, et al. A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients. Alcohol Clin Exp Res. 2012;36(8):1421–30.

PubMed Central CAS PubMed Google Scholar

Mitchell JM, Grossman LE, Coker AR, Messing RO. The anticonvulsant levetiracetam potentiates alcohol consumption in non-treatment seeking alcohol abusers. J Clin Psychopharmacol. 2012;32(2):269–72.

CAS PubMed Google Scholar

Richter C, Effenberger S, Bschor T, Bonnet U, Haasen C, Preuss UW, et al. Efficacy and safety of levetiracetam for the prevention of alcohol relapse in recently detoxified alcohol-dependent patients: a randomized trial. J Clin Psychopharmacol. 2012;32(4):558–62.

CAS PubMed Google Scholar

Le Strat Y. Levetiracetam in the treatment of alcohol dependence: toward the end of the story? Alcohol Clin Exp Res. 2012;36(8):1309–10.

PubMed Google Scholar

Knapp CM, Ciraulo DA, Sarid-Segal O, Richardson MA, Devine E, Streeter CC, et al. Zonisamide, topiramate, and levetiracetam: efficacy and neuropsychological effects in alcohol use disorders. J Clin Psychopharmacol. 2015;35(1):34–42.

PubMed Central CAS PubMed Google Scholar

Karam-Hage M, Brower KJ. Gabapentin treatment for insomnia associated with alcohol dependence. Am J Psychiatry. 2000;157(1):151.

CAS PubMed Google Scholar

Karam-Hage M, Brower KJ. Open pilot study of gabapentin versus trazodone to treat insomnia in alcoholic outpatients. Psychiatry Clin Neurosci. 2003;57(5):542–4.

PubMed Central CAS PubMed Google Scholar

Brower KJ, Myra Kim H, Strobbe S, Karam-Hage MA, Consens F, Zucker RA. A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. Alcohol Clin Exp Res. 2008;32(8):1429–38.

PubMed Central CAS PubMed Google Scholar

Bisaga A, Evans SM. The acute effects of gabapentin in combination with alcohol in heavy drinkers. Drug Alcohol Depend. 2006;83(1):25–32.

CAS PubMed Google Scholar

Myrick H, Anton R, Voronin K, Wang W, Henderson S. A double-blind evaluation of gabapentin on alcohol effects and drinking in a clinical laboratory paradigm. Alcohol Clin Exp Res. 2007;31(2):221–7.

CAS PubMed Google Scholar

Furieri FA, Nakamura-Palacios EM. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007;68(11):1691–700.

CAS PubMed Google Scholar

Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA InternMed. 2014;174(1):70–7.

CAS Google Scholar

Anton RF, Myrick H, Baros AM, Latham PK, Randall PK, Wright TM, et al. Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms. J Clin Psychopharmacol. 2009;29(4):334–42.

CAS PubMed Google Scholar

Anton RF, Myrick H, Wright TM, Latham PK, Baros AM, Waid LR, et al. Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatry. 2011;168(7):709–17.

PubMed Central PubMed Google Scholar

Martinotti G, Di Nicola M, Tedeschi D, Andreoli S, Reina D, Pomponi M, et al. Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial. J Psycho pharmacol. 2010;24(9):1367–74.

CAS Google Scholar

Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361(9370):1677–85.

CAS PubMed Google Scholar

Johnson BA, Ait-Daoud N, Akhtar FZ, Ma JZ. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. Arch Gen Psychiatry. 2004;61(9):905–12.

CAS PubMed Google Scholar

Johnson BA, Ait-Daoud N, Akhtar FZ, Javors MA. Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial. Arch Intern Med. 2005;165(14):1600–5.

CAS PubMed Google Scholar

Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007;298(14):1641–51.

CAS PubMed Google Scholar

Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, et al. Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch Intern Med. 2008;168(11):1188–99.

CAS PubMed Google Scholar

De Sousa AA, De Sousa J, Kapoor H. An open randomized trial comparing disulfiram and topiramate in the treatment of alcohol dependence. J Subst Abuse Treat. 2008;34(4):460–3.

PubMed Google Scholar

Florez G, Garcia-Portilla P, Alvarez S, Saiz PA, Nogueiras L, Bobes J. Using topiramate or naltrexone for the treatment of alcohol-dependent patients. Alcohol Clin Exp Res. 2008;32(7):1251–9.

CAS PubMed Google Scholar

Baltieri DA, Daro FR, Ribeiro PL, de Andrade AG. Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction. 2008;103(12):2035–44.

PubMed Google Scholar

Florez G, Saiz PA, Garcia-Portilla P, Alvarez S, Nogueiras L, Bobes J. Topiramate for the treatment of alcohol dependence: comparison with naltrexone. Eur Addict Res. 2011;17(1):29–36.

PubMed Google Scholar

Johnson BA, Ait-Daoud N. Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients. Curr Pharm Des. 2010;16(19):2103–12.

PubMed Central CAS PubMed Google Scholar

Paparrigopoulos T, Tzavellas E, Karaiskos D, Kourlaba G, Liappas I. Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study. BMC Psychiatry. 2011;11:41.

PubMed Central CAS PubMed Google Scholar

Batki SL, Pennington DL, Lasher B, Neylan TC, Metzler T, Waldrop A, et al. Topiramate treatment of alcohol use disorder in veterans with posttraumatic stress disorder: a randomized controlled pilot trial. Alcohol Clin Exp Res. 2014;38(8):2169–77.

CAS PubMed Google Scholar

Martinotti G, Di Nicola M, De Vita O, Hatzigiakoumis DS, Guglielmo R, Santucci B, et al. Low-dose topiramate in alcohol dependence: a single-blind, placebo-controlled study. J Clin Psychopharmacol. 2014;34(6):709–15.

CAS PubMed Google Scholar

Miranda R Jr, MacKillop J, Monti PM, Rohsenow DJ, Tidey J, Gwaltney C, et al. Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study. Alcohol Clin Exp Res. 2008;32(3):489–97.

CAS PubMed Google Scholar

Rubio G, Martinez-Gras I, Manzanares J. Modulation of impulsivity by topiramate: implications for the treatment of alcohol dependence. J Clin Psychopharmacol. 2009;29(6):584–9.

CAS PubMed Google Scholar

Likhitsathian S, Saengcharnchai P, Uttawichai K, Yingwiwattanapong J, Wittayanookulluk A, Srisurapanont M. Cognitive changes in topiramate-treated patients with alcoholism: a 12-week prospective study in patients recently detoxified. Psychiatry Clin Neurosci. 2012;66(3):235–41.

CAS PubMed Google Scholar

Ray LA, Miranda R Jr, MacKillop J, McGeary J, Tidey JW, Rohsenow DJ, et al. A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. Exp Clin Psychopharmacol. 2009;17(2):122–9.

PubMed Central CAS PubMed Google Scholar

Kranzler HR, Gelernter J, Anton RF, Arias AJ, Herman A, Zhao H, et al. Association of markers in the 3’ region of the GluR5 kainate receptor subunit gene to alcohol dependence. Alcohol Clin Exp Res. 2009;33(5):925–30.

PubMed Central CAS PubMed Google Scholar

Kranzler HR, Covault J, Feinn R, Armeli S, Tennen H, Arias AJ, et al. Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am J Psychiatry. 2014;171(4):445–52.

PubMed Central PubMed Google Scholar

Kranzler HR, Armeli S, Tennen H, Gelernter J, Covault J. GRIK1 genotype and daily expectations of alcohol’s positive effects moderate the reduction of heavy drinking by topiramate. Exp Clin Psychopharmacol. 2014;22(6):494–501.

CAS PubMed Google Scholar

Kranzler HR, Armeli S, Wetherill R, Feinn R, Tennen H, Gelernter J, et al. Self-efficacy mediates the effects of topiramate and GRIK1 genotype on drinking. Addict Biol. 2014. doi:10.1111/adb.12207

Likhitsathian S, Uttawichai K, Booncharoen H, Wittayanookulluk A, Angkurawaranon C, Srisurapanont M. Topiramate treatment for alcoholic outpatients recently receiving residential treatment programs: a 12-week, randomized, placebo-controlled trial. Drug Alcohol Depend. 2013;133(2):440–6.

CAS PubMed Google Scholar

Kampman KM, Pettinati HM, Lynch KG, Spratt K, Wierzbicki MR, O’Brien CP. A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence. Drug Alcohol Depend. 2013;133(1):94–9.

PubMed Central CAS PubMed Google Scholar

Blodgett JC, Del Re AC, Maisel NC, Finney JW. A meta-analysis of topiramate’s effects for individuals with alcohol use disorders. Alcohol Clin Exp Res. 2014;38(6):1481–8.

CAS PubMed Google Scholar

Falk D, Wang XQ, Liu L, Fertig J, Mattson M, Ryan M, et al. Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials. Alcohol Clin Exp Res. 2010;34(12):2022–34.

PubMed Google Scholar

Sarid-Segal O, Knapp CM, Burch W, Richardson MA, Bahtia S, DeQuattro K, et al. The anticonvulsant zonisamide reduces ethanol self-administration by risky drinkers. Am J Drug Alcohol Abuse. 2009;35(5):316–9.

PubMed Central PubMed Google Scholar

Knapp CM, Sarid-Segal O, Richardson MA, Colaneri LS, Afshar M, Devine E, et al. Open label trial of the tolerability and efficacy of zonisamide in the treatment of alcohol dependence. Am J Drug Alcohol Abuse. 2010;36(2):102–5.

PubMed Google Scholar

Rubio G, Lopez-Munoz F, Ferre F, Martinez-Gras I, Ponce G, Pascual JM, et al. Effects of zonisamide in the treatment of alcohol dependence. Clin Neuropharmacol. 2010;33(5):250–3.

Arias AJ, Feinn R, Oncken C, Covault J, Kranzler HR. Placebo-controlled trial of zonisamide for the treatment of alcohol dependence. J Clin Psychopharmacol. 2010;30(3):318–22.

PubMed Central CAS PubMed Google Scholar

American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition (DSM-IV). Washington, DC: Am Psychiatr Assoc; 1994.

Google Scholar

American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fifth edition (DSM-5). Washington, DC: Am Psychiatr Assoc; 2013.

Google Scholar

American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition, text revision (DSM-IV-TR). Washington, DC: Am Psychiatr Assoc; 2000.

Google Scholar

Ebell MH, Siweck J, Weiss BD, Woolf SH, Ewigman B, Bowman M. Strength of recommendation taxonomy (SORT): a patientcentered approach to grading evidence in medical literature. Am Fam Physician. 2004;69(3):548–56.

PubMed Google Scholar

Download references

Acknowledgments

Funding source: Dr. Niciu receives salary support from the Intramural Research Program at the National Institutes of Health/National Institute of Mental Health (IRP-NIMH-NIH).